N
Nuvalent, Inc. (NUVL)
NMS – Real Time Price. Currency in USD
123.52
-0.01 (-0.01%)
At close: Jun 26, 2026, 4:00 PM EDT
123.75
+0.23 (0.19%)
After-hours: Jun 26, 2026, 6:58 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
123.52
-0.01 (-0.01%)
At close: Jun 26, 2026, 4:00 PM EDT
123.75
+0.23 (0.19%)
After-hours: Jun 26, 2026, 6:58 PM EDT
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. Nuvalent, Inc. has a strategic partnership with Guardant Health, Inc. to develop companion diagnostics therapies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
| Name | Position |
|---|---|
| Chelcie Lister | Senior Director of Investor Relations & Corporate Communications |
| Dr. Benjamin Lane Ph.D. | Chief Technical Operations Officer |
| Dr. Christopher D. Turner M.D. | Chief Medical Officer |
| Dr. Henry Pelish Ph.D. | Chief Scientific Officer |
| Dr. James R. Porter Ph.D. | CEO, President & Director |
| Mr. John Soglia Ph.D. | Senior Vice President of Translational Development |
| Date | Type | Document |
|---|---|---|
| 2026-06-24 | SC TO-T | d90297dsctot.htm |
| 2026-06-18 | 8-K | nuvl-20260616.htm |
| 2026-06-09 | SC TO-C | d29899dsctoc.htm |
| 2026-06-09 | 8-K | d137459d8k.htm |
| 2026-05-07 | 8-K | nuvl-20260507.htm |
| 2026-05-07 | 10-Q | nuvl-20260331.htm |
| 2026-04-28 | DEFA14A | nuvl-defa14a-2026.htm |
| 2026-04-28 | DEF 14A | nuvl-20260428.htm |
| 2026-04-28 | ARS | nuvl-annual_report-2025.pdf |
| 2026-04-07 | 8-K | nuvl-20260407.htm |
| Mr. Joshua Horan Ph.D. | Senior Vice President of Chemistry |
| Ms. Darlene Noci | Chief Development Officer |
| Ms. Deborah Ann Miller J.D., Ph.D. | Chief Legal Officer & Secretary |
| Ms. Ruth Adams | Senior Vice President of Clinical Operations |